The lowest manufactured dose of Plavix (clopidogrel) is 75 mg. The FDA approves only two tablet strengths: 75 mg and 300 mg. There is no 50 mg or 25 mg tablet on the market in the United States, though lower doses are used clinically in parts of East Asia.
Available Tablet Strengths
Plavix comes as a pink, round, film-coated 75 mg tablet and a pink, oblong 300 mg tablet. The 75 mg tablet is the standard daily maintenance dose for preventing blood clots after a heart attack, stroke, or stent placement. The 300 mg tablet is used as a one-time loading dose, meaning you take it once at the start of treatment to get the drug working quickly, then step down to 75 mg per day.
If your doctor prescribes Plavix, the lowest pill you can pick up at a pharmacy is 75 mg. Splitting the tablet to get a smaller dose is not something guidelines recommend, and doing so without medical guidance could leave you underprotected against clots or create inconsistent dosing.
How the Standard Dose Is Used
The 2025 guidelines from the American College of Cardiology and American Heart Association lay out two scenarios. For most patients with acute coronary syndrome (a heart attack or unstable angina), the loading dose is 300 mg or 600 mg taken once, followed by 75 mg daily. For patients over 75 who received clot-dissolving medication, the loading dose is skipped entirely and treatment begins at 75 mg daily. In both cases, 75 mg per day is the long-term maintenance dose.
Lower Doses Used in Japan and East Asia
Outside the U.S., some countries do use doses below 75 mg. In Japan, it is common practice to reduce clopidogrel from 75 mg daily during the first three months of treatment to 50 mg daily from months three through twelve, then further reduce to 25 mg after one year. These lower doses are not available as branded Plavix tablets but can be achieved through compounding or locally manufactured generics.
A randomized pilot trial in Japanese patients found that 50 mg of clopidogrel had similar efficacy and safety to 75 mg, with no cases of cardiac death, heart attack, or stent clotting in either group over roughly 22 months of follow-up. A separate retrospective study in Chinese patients reached a similar conclusion: 50 mg appeared comparable to 75 mg for patients who had already completed at least 12 months of dual antiplatelet therapy after stent placement.
The reason lower doses may work in these populations comes down to genetics. A liver enzyme called CYP2C19 converts clopidogrel into its active form. Variants that make this enzyme less active are more common in East Asian populations. Paradoxically, this means the drug’s blood-thinning effect is already somewhat reduced at 75 mg in many East Asian patients, so lowering the dose further doesn’t necessarily drop protection below a useful threshold. It also means bleeding risk stays lower. This genetic pattern is less common in European and African-descent populations, which is one reason Western guidelines have not adopted reduced dosing.
Why Doctors Sometimes Want a Lower Dose
The most common reason to consider a dose below 75 mg is bleeding. Clopidogrel works by blocking a receptor on platelets that helps them clump together. That’s exactly what you want after a stent or heart attack, but it also means cuts heal more slowly, bruising comes easier, and the risk of serious bleeding (particularly in the stomach or brain) goes up. For patients who are older, weigh less, or have a history of bleeding problems, a lower dose is appealing because it might preserve enough clot protection while reducing bleeding events.
A related strategy called “de-escalation” has gained traction in cardiology. Rather than lowering the clopidogrel dose specifically, some doctors switch patients from a stronger antiplatelet drug to clopidogrel 75 mg after the highest-risk window (typically the first one to three months after a stent). This gives full-strength protection early on, then dials back intensity when the stent has had time to heal and the risk of clotting drops. Trials testing this approach with other antiplatelet medications have shown reduced bleeding without an increase in heart attacks or stent problems.
What This Means Practically
If you’re taking Plavix in the U.S. or Europe, 75 mg is the lowest dose you’ll be prescribed under current guidelines. There is no half-strength tablet to ask for. If bleeding side effects are a concern, the conversation with your doctor is more likely to focus on how long you stay on the medication, whether you need to be on aspirin at the same time, or whether a different antiplatelet drug might suit you better.
For patients of East Asian descent, some cardiologists are aware of the data supporting 50 mg maintenance dosing and may consider it on a case-by-case basis, particularly after the first year of treatment. This remains an off-label approach outside of Japan, and the evidence supporting it, while promising, comes from relatively small studies rather than the large-scale trials that shaped the 75 mg recommendation.